# Tenon Medical, Inc.

> Tenon Medical is a Los Gatos, California medical device company that built the Catamaran SI Joint Fusion System, a patented, less-invasive way to fuse the sacroiliac joint with a single titanium implant placed along an inferior-posterior trajectory. Founded in 2012 and public on the Nasdaq since 2022 (TNON), Tenon targets the often-overlooked SI joint, a frequent and hard-to-diagnose source of chronic lower-back pain. In 2025 it expanded into a multi-product sacro-pelvic platform by acquiring the SiVantage SImmetry technology portfolio.

- **Founded:** 2012
- **Headquarters:** Los Gatos, California, United States
- **Founders:** Richard Ferrari (Co-Founder, Director & Executive Chairman), Richard Ginn (Co-Founder, Chief Technology Officer & COO)
- **Team size:** ~27 employees
- **Products:** Catamaran SI Joint Fusion System, MAINSAIL Study, SImmetry / SImmetry+ (via SiVantage)
- **Notable:** Received FDA 510(k) clearance for the Catamaran SI-Joint Fusion System in 2018, Completed IPO and listed on Nasdaq (TNON) in April 2022, Nationally launched the Catamaran System at the NASS meeting in October 2022

## Products & services

- **Catamaran SI Joint Fusion System** — FDA-cleared (2018) patented system that places a single titanium implant directly across the sacroiliac joint using an inferior-posterior trajectory through dense cortical bone, optimized under fluoroscopic guidance for biomechanical stability and autologous bone integration.
- **MAINSAIL Study** — An IRB-approved, prospective, multi-center, post-market clinical investigation of the Catamaran system reporting pain reduction, fusion rates and patient satisfaction out to 12 months.
- **SImmetry / SImmetry+ (via SiVantage)** — Lateral-approach SI joint fusion technologies acquired in 2025, expanding Tenon into a multi-approach sacro-pelvic fusion portfolio.

## Achievements

- Received FDA 510(k) clearance for the Catamaran SI-Joint Fusion System in 2018
- Completed IPO and listed on Nasdaq (TNON) in April 2022
- Nationally launched the Catamaran System at the NASS meeting in October 2022
- Published two peer-reviewed MAINSAIL study papers showing durable 12-month outcomes
- Reported 83% fusion success and 83.3% patient satisfaction at 12 months
- Grew full-year 2025 revenue 20% to $3.9M with Q4 up 92% year over year
- Acquired the SiVantage SImmetry portfolio in 2025 to become a multi-approach platform

## Latest updates

- **2026-03** — Reported Q4 and full-year 2025 results: full-year revenue of $3.9M (+20%), record gross profit of $2.4M (+38%), Q4 revenue up 92%.
- **2026-05** — Reported Q1 2026 revenue of $1.4M, up approximately 90% year over year.
- **2025-08** — Acquired the SiVantage SImmetry / SImmetry+ SI joint fusion technology portfolio, expanding its sacro-pelvic fusion offering.
- **2025-06** — Announced second peer-reviewed Catamaran MAINSAIL study publication confirming durable clinical outcomes to 12 months.

## Links

- Website: https://tenonmed.com
- LinkedIn: http://www.linkedin.com/company/tenon-medical-inc

---

Profile page: https://yespress.io/tenon-medical-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-11